ESC Premium Access

Clinical Trial Update 1

Event: ESC CONGRESS 2017
Topic: Miscellaneous
Session type: Clinical Trial Update
Date: 28 August 2017
Time: 14:00 - 15:30

Session

6 presentations in this session

Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT

Speaker: Professor T. Wang (Taipei, TW)
Thumbnail

Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: the AFFIRM Study

Speaker: Doctor M. Proietti (Milan, IT)
Thumbnail

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Speaker: Doctor R. Giugliano (Boston, US)
Thumbnail

The long-term efficacy and safety of short dual antiplatelet therapy

Speaker: Professor M. Nakamura (Tokyo, JP)
Thumbnail

Mechanisms for the benefit of spironolactone in resistant hypertension in the PATHWAY-2 study

Speaker: Professor B. Williams (London, GB)
Thumbnail

Aldosterone Lethal Effects Blocked in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up

Speaker: Professor F. Beygui (Caen, FR)
Thumbnail

6 speakers from this session

Professor Tzung-Dau Wang

National Taiwan University Hospital, Taipei (Taiwan)
4 presentations
0 follower

Doctor Marco Proietti

University of Milan, Milan (Italy)
4 presentations
0 follower

Doctor Robert Patrick Giugliano

Brigham and Women's Hospital, Department of Medicine, Cardiovascular Division, TIMI Study Group, Boston (United States of America)
9 presentations
0 follower

Professor Masato Nakamura

Toho University Ohashi Medical Center, Tokyo (Japan)
3 presentations
0 follower

Professor Bryan Williams

University College London, London (United Kingdom of Great Britain & Northern Ireland)
50 presentations
1 follower

Professor Farzin Beygui

University Hospital of Caen, Caen (France)
4 presentations
0 follower

This platform is supported by

logo Novo Nordisk